Results 101 to 110 of about 61,821 (357)

Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy

Advanced Science, EarlyView.
Engineered microparticles co‐delivering geldanamycin and dual nanobodies induce targeted pyroptosis and block PD‐L1 and CD47 pathways, reprogramming the tumor microenvironment and achieving potent antitumor immunity in lung cancer models with minimal toxicity.
Tianli Hao, Zihan Deng, Yufei Liu, Li Liu, Deqiang Deng, Muyang Yang, Yuanyuan Geng, Yao Sun, Beilei Yue, Jonathan F. Lovell, Yushuai Liu, Lisen Lu, Honglin Jin   +12 more
wiley   +1 more source

The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia

Current Issues in Molecular Biology
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It is characterized by the clonal proliferation of mature B cells. The tumor microenvironment (TME) seems to play a crucial role in the survival and proliferation of tumor cells ...
Khalil Saleh, Ahmadreza Arbab, Nadine Khalife, Rita Khoury, Rebecca Ibrahim, Mohamad Ali Hachem, Cynthia Khalil, Cendrella Bou Orm, Joud Sawan, Geoffroy Lafarge, Nohad Masri, Zamzam Tikriti, Claude Chahine, Axel Le Cesne   +13 more
doaj   +1 more source

Decoding the Mechanism of Action of a Parasite TGFβ Antagonist Inspires the Creation of Cell‐Type‐Specific TGFβ Modulators

Advanced Science, EarlyView.
The mammalian TGFβ interacts with ubiquitously expressed TGFBR1 and TGFBR2, and current TGFβ‐targeting agents are non‐cell‐selective. The cooperative interaction of the modular parasite TGFβ antagonist with multiple host (co‐)receptors empowers the design of TGM chimeras and bispecific antibodies that activate or inhibit TGFβ signaling in a cell ...
Maarten van Dinther, Tristin Schwartze, Jiying Zhang, Kun Fan, Gerard van der Zon, Luke Power, Cynthia S. Hinck, Claire Ciancia, Ananya Mukundan, Roman Gonzalez‐Prieto, Peter van Veelen, Rick M. Maizels, Andrew P. Hinck, Peter ten Dijke   +13 more
wiley   +1 more source

Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific

Cell Reports Medicine
Summary: Metastatic uveal melanoma is an aggressive disease with poor outcome, which is refractory to immune checkpoint inhibitors. A T cell receptor (TCR)-based CD3 bispecific, tebentafusp, delivers clinical benefit in patients with metastatic uveal ...
Joseph J. Sacco, Peter Kirk, Emma Leach, Alexander N. Shoushtari, Richard D. Carvajal, Camille Britton-Rivet, Sophie Khakoo, Laura Collins, Luis de la Cruz-Merino, Zeynep Eroglu, Alexandra P. Ikeguchi, Paul Nathan, Omid Hamid, Marcus O. Butler, Sarah Stanhope, Koustubh Ranade, Takami Sato   +16 more
doaj   +1 more source

Expression of an anti-CD33 single-chain antibody by Pichia pastoris [PDF]

, 2005
CD33 is a cell surface glycoprotein expressed on cells of myelomonocytic lineage, leukaemic cells, but not haematopoietic stem cells. By virtue of its expression pattern, CD33 has become a popular target for new immunotherapeutic approaches to treat ...
Emberson, Louise M., Trivett, Amanda J., Blower, Philip J., Nicholls, Peter J.   +3 more
core   +1 more source

POS0206 DESIGN AND CHARACTERISATION OF A THERAPEUTIC BISPECIFIC TANDEM scFv-Fc FUSION PROTEIN WITH ANTI-TNF AND SYNOVIUM-TARGETING SPECIFICITY FOR THE TREATMENT OF RHEUMATOID ARTHRITIS [PDF]

, 2021
S. Pagani, Federico Colombo, Costantino Pitzalis   +2 more
openalex   +1 more source

Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy

Advanced Science, EarlyView.
ZIFOA‐M is engineered by conjugating oncolytic adenovirus‐loaded ZIF‐8 nanoparticles onto macrophage surfaces via bioorthogonal chemistry. Upon tumor infiltration, the platform releases OA to downregulate CD47/CD24 on tumor cells, restoring macrophage phagocytosis.
Jilong Wang, Ning Lu, Zhuo Yan, Luyi Ye, Luyao Bai, Shanshan Yuan, Yuting Zhu, Yiru Xiong, Yongheng Bai, Yaping Chen, Junjie Deng   +10 more
wiley   +1 more source

Homogeneous Bispecifics by Disulfide Bridging

Bioconjugate Chemistry, 2014
We report on a chemical platform to generate site-specific, homogeneous, antibody-antibody conjugates by targeting and bridging disulfide bonds. A bispecific antibody construct was produced in good yield through simple reduction and bridging of antibody fragment disulfide bonds, using a readily synthesized bis-dibromomaleimide cross-linker.
Hull, EA, Livanos, M, Miranda, E, Smith, ME, Chester, KA, Baker, JR   +5 more
openaire   +3 more sources

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET [PDF]

, 2021
Joost Neijssen, Rosa M. F. Cardoso, Kristen Chevalier, Luus Wiegman, Thomas Valerius, Geoffrey M. Anderson, Sheri L. Moores, Janine Schuurman, Paul W.H.I. Parren, William R. Strohl, Mark L. Chiu   +10 more
openalex   +1 more source